ENXTPA:EOSI

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

EOS imaging SA designs, develops, markets, and sells medical imaging devices for osteo-articular conditions and orthopedics, and related applications.


Snowflake Analysis

Limited growth with imperfect balance sheet.


Similar Companies

Share Price & News

How has EOS imaging's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: EOSI's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

0.9%

EOSI

-11.5%

FR Medical Equipment

8.7%

FR Market


1 Year Return

-16.8%

EOSI

42.8%

FR Medical Equipment

-2.4%

FR Market

Return vs Industry: EOSI underperformed the French Medical Equipment industry which returned 47.4% over the past year.

Return vs Market: EOSI underperformed the French Market which returned -3.8% over the past year.


Shareholder returns

EOSIIndustryMarket
7 Day0.9%-11.5%8.7%
30 Day0.2%-1.9%15.9%
90 Day-49.2%35.6%1.3%
1 Year-16.8%-16.8%42.8%42.8%-0.7%-2.4%
3 Year-75.6%-75.6%43.9%42.1%11.2%2.2%
5 Year-73.3%-73.3%144.9%139.2%31.1%14.3%

Price Volatility Vs. Market

How volatile is EOS imaging's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is EOS imaging undervalued compared to its fair value and its price relative to the market?

2.88x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate EOSI's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate EOSI's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: EOSI is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: EOSI is unprofitable, so we can't compare its PE Ratio to the French market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate EOSI's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: EOSI is overvalued based on its PB Ratio (2.9x) compared to the FR Medical Equipment industry average (2.6x).


Next Steps

Future Growth

How is EOS imaging forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

21.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: EOSI is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: EOSI is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: EOSI is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: EOSI's revenue (31.8% per year) is forecast to grow faster than the French market (3.9% per year).

High Growth Revenue: EOSI's revenue (31.8% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if EOSI's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has EOS imaging performed over the past 5 years?

-28.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: EOSI is currently unprofitable.

Growing Profit Margin: EOSI is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: EOSI is unprofitable, and losses have increased over the past 5 years at a rate of -28.2% per year.

Accelerating Growth: Unable to compare EOSI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: EOSI is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-1.8%).


Return on Equity

High ROE: EOSI has a negative Return on Equity (-152.58%), as it is currently unprofitable.


Next Steps

Financial Health

How is EOS imaging's financial position?


Financial Position Analysis

Short Term Liabilities: EOSI's short term assets (€44.6M) exceed its short term liabilities (€23.1M).

Long Term Liabilities: EOSI's short term assets (€44.6M) exceed its long term liabilities (€29.7M).


Debt to Equity History and Analysis

Debt Level: EOSI's debt to equity ratio (218.4%) is considered high.

Reducing Debt: EOSI's debt to equity ratio has increased from 14.1% to 218.4% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: EOSI has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: EOSI has less than a year of cash runway if free cash flow continues to reduce at historical rates of 5.9% each year


Next Steps

Dividend

What is EOS imaging's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate EOSI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate EOSI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if EOSI's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if EOSI's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of EOSI's dividend in 3 years as they are not forecast to pay a notable one for the French market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.6yrs

Average management tenure


CEO

Mike Lobinsky

1.42yrs

Tenure

Mr. Mike Lobinsky is Chief Executive Officer of EOS imaging SA since January 1, 2019 and serves as its Director. He was President of North America at EOS imaging SA since joining in August 2017 until Decem ...


Leadership Team

NamePositionTenureCompensationOwnership
Mike Lobinsky
CEO & Director1.42yrsno datano data
Valérie Worrall
Chief Financial Officer1.58yrsno datano data
Eric Maulavé
Chief Operating Officer2.67yrsno datano data
Carl Denys
Vice President of Global Marketing0.42yrno datano data
Elisabeth Soubelet
Chief Medical Officer4.83yrsno datano data
Youcef Imoussaine
Field Maintenance Directorno datano datano data

1.6yrs

Average Tenure

Experienced Management: EOSI's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Mike Lobinsky
CEO & Director1.42yrsno datano data
Marie Meynadier
Directorno data€682.70k1.41% 489.3k
Gérard Hascoët
Chairman of the Board4.92yrs€65.00k0.013% 4.6k
Eric Beard
Independent Director8yrs€30.00kno data
Marie-Laure Garrigues
Director8.5yrsno datano data
Antoine Vidal
Director1.5yrsno datano data

6.5yrs

Average Tenure

68yo

Average Age

Experienced Board: EOSI's board of directors are considered experienced (6.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: EOSI insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

EOS imaging SA's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: EOS imaging SA
  • Ticker: EOSI
  • Exchange: ENXTPA
  • Founded: 1989
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: €34.765m
  • Shares outstanding: 26.50m
  • Website: https://www.eos-imaging.com

Number of Employees


Location

  • EOS imaging SA
  • 10 rue Mercœur
  • Paris
  • Ile-de-France
  • 75011
  • France

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
EOSIENXTPA (Euronext Paris)YesCommon StockFREURFeb 2012
0QARLSE (London Stock Exchange)YesCommon StockGBEURFeb 2012
EOSIPBATS-CHIXE (BATS 'Chi-X Europe')YesCommon StockGBEURFeb 2012
EOSG.FOTCPK (Pink Sheets LLC)YesCommon StockUSUSDFeb 2012

Biography

EOS imaging SA designs, develops, markets, and sells medical imaging devices for osteo-articular conditions and orthopedics, and related applications. It offers EOS, an imaging system that provides low dose, full body, and stereo-radiographic images of patient in a functional position; EOSedge, an X-ray system that provides images quality for patients; sterEOS, a 3D modeling workstation that analyzes frontal and lateral EOS images which are captured simultaneously and registered to generate precise, patient-specific, and 3D models of the spine and/or lower limbs from weight-bearing, low dose, or Micro Dose EOS exams; and EOSapps, an online 3D surgical planning solutions based on unbiased, weight-bearing EOS images, and an accurate 2D/3D patient-specific data set. The company also provides 3D surgical planning software and patient-specific instruments for hip and knee arthroplasties. It sells its products in Europe, the Middle East, Africa, North Africa, and the Asia-Pacific. The company was formerly known as biospace med and changed its name to EOS Imaging SA in 2010. EOS imaging SA was founded in 1989 and is headquartered in Paris, France. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/06/05 23:16
End of Day Share Price2020/06/05 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.